Effect of thyroid hormone on the abundance of Na,K-adenosine triphosphatase alpha-subunit messenger ribonucleic acid.

The effects of thyroid hormone on Na,K-ATPase alpha-subunit mRNA (mRNA alpha) content and Na,K-ATPase activity were measured in renal cortex, heart, and cerebrum of hypothyroid rats 24 and 72 h after injection of diluent or T3. Use of a cDNA probe complementary to rat brain mRNA alpha in Northern blot analysis revealed a single 26-27 S band in RNA isolated from these three tissues regardless of thyroid status. Tissue mRNA alpha content was estimated by dot blot analysis of whole cell extracts and isolated total RNA. Injection of T3 augmented mRNA alpha content by 2.1- to 2.5-fold in kidney cortex and myocardium at 24 h. After three daily injections of T3, the increases in mRNA alpha were evident despite a global increase in RNA content associated with hypertrophy of these target tissues. Furthermore, the increases in abundance of mRNA alpha after 72 h of T3 treatment correlated with enhancement of Na,K-ATPase activity. In contrast, both mRNA alpha and enzyme activity were invariant in the cerebrum. These data suggest that T3-induced augmentation of Na,K-ATPase activity is mediated, at least in part, by increased mRNA alpha content in target tissues.

Glucocorticoid stimulation of growth hormone messenger ribonucleic acid levels in GH3 cells is inhibited by calcium but not by somatostatin.

Aside from studies of a possible synergism between T3 and glucocorticoids in regulating GH mRNA, there have been few previous studies of the modulation by hormones and other factors of glucocorticoid hormone regulation of pituitary cell GH gene expression. We have employed a serum-free medium containing no exogenously added Ca2+ to investigate whether Ca2+ or somatostatin influences the stimulation by the synthetic glucocorticoid dexamethasone of GH mRNA levels in GH3 cells. Basal levels were slightly (less than or equal to 2-fold) stimulated by CaCl2 (0.4 mM). The stimulation by dexamethasone (100 nM) of GH mRNA in GH3 cells incubated in serum-free medium with or without Ca2+ was, respectively, 20- and 25-fold. Thus, under these experimental conditions, little effect of Ca2+ on regulation by dexamethasone was observed. To further reduce Ca2+ levels in the incubation medium, EGTA (20 microM) was added to chelate residual Ca2+. In some but not all experiments, EGTA treatment yielded a slight decrease in basal GH mRNA levels. Time-course experiments performed in the presence of EGTA showed that during incubation periods with dexamethasone that yielded a detectable stimulation of GH mRNA (2-4 days), Ca2+ (0.4 mM) inhibited the dexamethasone stimulation by 3- to 5-fold. Investigations of the dose-response relationship of the effect of dexamethasone on GH mRNA performed under the same conditions showed that at dexamethasone concentrations that yielded a significant stimulation of GH mRNA (10 nM or greater), Ca2+ (0.4 mM) inhibited the dexamethasone stimulation by about 2-fold. In contrast to the inhibitory effects of Ca2+ on the stimulation by dexamethasone of GH mRNA in the GH3 cells, somatostatin had no effect at any concentration tested (1-1000 nM) on dexamethasone regulation of this mRNA.

Growth hormone (GH)-releasing factor does not regulate GH release or GH mRNA levels in GH3 cells.

Previous studies have shown that GH-releasing factor (GRF) regulates both GH production and GH mRNA levels in primary cultures of rat pituitary cells. Investigations were carried out to ascertain the ability of GRF to regulate GH production or mRNA levels in a clonal strain of rat pituitary tumor (GH3) cells. Incubation of the cells with GRF at 1-1000 nM for 4 h to 10 days did not result in a stimulation of GH or PRL production, nor did it affect the cytoplasmic levels of the corresponding mRNAs. The lack of response to GRF was not affected by dexamethasone, T3, or serum. We conclude that GH3 cells do not provide a useful model system for studies of the mechanism(s) of action of GRF on either GH release or GH gene expression.

Reduced Cd2+ accumulation and elevated metallothionein levels in a Cd2+ and Zn2+-resistant clonal CHO-K1 cell line.

A clonal cell line, R40F, was selected from a heterogenous population of Cd2+ and Zn2+-resistant CHO-K1 cells. These R40F cells demonstrated resistance to 120- and 4-fold higher concentrations of Cd2+ and Zn2+, respectively, than did wild type CHO-K1 cells. When cultured in the presence of low concentrations of Cd2+ (0.5-1.0 microM), the accumulation of intracellular Cd2+ in R40F cells appears to be significantly less than in wild type cells. Since R40F cells maintained in medium containing high concentrations of Cd2+ (200 microM) retain levels of Cd2+ equivalent to the intracellular concentration observed in wild type cells exhibiting cytotoxicity, it is assumed that reduced Cd2+ transport alone is unlikely to account for the resistance to Cd2+ toxicity. Exposure of R40F cells to non-toxic (2 microM or 100 microM) or toxic (200 microM) Zn2+ levels resulted in an accumulation of Zn2+ equal to, or greater than, that observed in the wild type cell. When compared to the basal level in uninduced wild type cells, metallothionein levels were elevated 14- and 23-fold, respectively, in R40F cells cultured in the presence of 0.5 microM Cd2+ and 100 microM Zn2+. These results are consistent with the hypothesis that R40F cells express Cd2+ and Zn2+ resistance as a consequence of a reduction in unbound intracellular Cd2+ levels and an elevation of metallothionein synthesis.

Regulation by calcium of prolactin and growth hormone mRNA sequences in primary cultures of rat pituitary cells.

Addition of Ca2+ to primary cultures of female pituitary cells incubated in serum-free medium lacking added Ca2+ yielded no effects on levels of prolactin or growth hormone mRNA, assayed by cytoplasmic dot hybridization. However, incubation of the cells in serum-free medium containing sufficient ethylene glycol bis(beta-aminoethyl ether)-N,N,N',N'-tetraacetic acid to reduce medium Ca2+ levels below the 10-40 microM present as a trace contaminant yielded a decrease in the levels of both mRNAs. The decrease was dose-dependent at extracellular Ca2+ concentrations below 1.0 microM, had an apparent half-maximum at about 0.3 microM, and did not appear to plateau with increasing incubation times. Following 2-3-day incubations of cells in low Ca2+, a reduction of prolactin mRNA (23-70-fold) consistently greater than the reduction of growth hormone mRNA (9-15-fold) was observed. Similar effects of reduced extracellular Ca2+ were obtained with primary cultures of male pituitary cells. The specificity of these effects of lowered extracellular Ca2+ was demonstrated by the following observations. The decreases in these mRNAs were substantially reversible by readdition of Ca2+ to the incubation medium. Reduction of extracellular Ca2+ led to no detectable changes in cellular ribosomal RNA levels or over-all RNA synthesis. In male pituitary cells, the level of another metal-regulated mRNA, that for metallothionein, was not decreased by a reduction of extracellular Ca2+ that caused a 40-fold decrease in levels of prolactin and growth hormone mRNA. Hence, Ca2+ exhibits specificity in its regulation of pituitary prolactin and growth hormone gene expression.

Amplification of the metallothionein-I gene in cadmium- and zinc-resistant Chinese hamster ovary cells.

A subclone of Chinese hamster ovary cells, R40F, has been selected for its unusually high resistance to lethal concentrations of Cd and Zn. Although there is a 33% loss in Cd resistance when R40F cells are cultured in the absence of exogenous metals, the Zn resistance remains unaltered. These cells are 80% tetraploid and demonstrate an increased capacity for metallothionein protein synthesis. When compared to wild type cells cultured in the absence of exogenous metals, R40F cells exposed to 200 M Cd for 48 h exhibited an approximate 200-fold increase in metallothionein-I (MT-I) protein. A 32P-labeled mouse MT-I cDNA was employed in solution hybridization studies to measure the level of MT-I mRNA in wild type and R40F cells. Cd (0.5 M) induces MT-I mRNA about 2.5- and 5-fold in wild type and resistant Chinese hamster ovary cells, respectively. When optimally induced, the resistant cells have about 80-fold more MT-I mRNA than the sensitive cells. Southern blot analysis of HincII-cleaved DNA indicates that the MT-I gene is amplified approximately 60- to 75-fold in R40F cells.

Thyroid hormone induction of Na(+)-K(+)-ATPase and its mRNAs in a rat liver cell line.

The expression of mRNAs encoding the alpha- and beta-subunits of Na(+)-K(+)-ATPase (Na(+)-K+ pump) was examined in a rat liver cell line, Clone 9, in various thyroidal states. Northern blot analysis of total RNA isolated from cells incubated in hypothyroid serum-containing medium revealed the expression of mRNAs encoding Na(+)-K(+)-ATPase alpha 1-(mRNA alpha 1) and beta- (mRNA beta) subunits; mRNAs encoding the alpha 2- and alpha 3-subunits were undetectable. There was a discrepancy in the abundance of mRNA alpha 1 relative to mRNA beta such that mRNA alpha 1 exceeded the sum of the multiple mRNA beta bands by approximately 35-fold. 3,3',5-Triiodothyronine (T3) produced a coordinate augmentation of mRNA alpha 1 and mRNA beta contents that was demonstrable within 2 h and preceded the stimulation of Na(+)-K(+)-ATPase activity. After incubation of cells with T3 for 48 h, Na(+)-K(+)-ATPase activity was stimulated by 1.32-fold, whereas mRNA alpha 1 and mRNA beta abundances were increased 1.46- and 2.87-fold, respectively. Treatment of cells for 6 h with 10 micrograms/ml cycloheximide, a concentration sufficient to inhibit protein synthesis by 95%, elicited a 3.5- and 5.1-fold increase in mRNA alpha 1 and mRNA beta content, respectively. Cycloheximide abrogated the stimulatory effect of T3 on mRNA beta abundance, whereas the T3-induced increase in mRNA alpha 1 content was not prevented.(ABSTRACT TRUNCATED AT 250 WORDS)

Thyroidal regulation of rat renal and hepatic Na,K-ATPase gene expression.

Na,K-ATPase activity, Na,K-ATPase alpha- and beta-subunit mRNA abundance (mRNA alpha and mRNA beta), and gene transcription rates were determined in kidney cortex and liver of hypothyroid and triiodothyronine (T3)-treated rats. In hypothyroid rats, Na,K-ATPase activity (expressed per unit of DNA) was 3.6-fold greater in kidney cortex than liver, and the abundance of mRNA alpha and mRNA beta in kidney cortex exceeded that of liver by 2.8- and 5.2-fold, respectively. In vitro nuclear run-on analysis revealed similar rates of Na,K-ATPase alpha and beta gene transcription in nuclei isolated from either kidney cortex or liver. Administration of T3 for 72 h elicited a 2.3-fold stimulation of renal Na,K-ATPase activity that was associated with a 3.1- and 2.6-fold increase of mRNA alpha and mRNA beta content, respectively. In contrast, T3 induced a 1.3-fold stimulation of liver Na,K-ATPase activity accompanied by a 7.3-fold increase in mRNA alpha and no change in mRNA beta abundance. Transcription rates of alpha and beta genes (assayed by nuclear run-on) in renal cortex were both stimulated 1.8-fold in response to T3 injection. Similarly in liver nuclei, T3 treatment produced a 1.4- and 1.3-fold stimulation in the rate of alpha and beta gene transcription, respectively. These results indicate that significant discrepancies exist in the quantitative relationships between control and T3-induced changes in renal and hepatic enzyme activity, mRNA abundance and rate of gene transcription, and imply that the T3-induced increase in Na,K-ATPase abundance is mediated at both transcriptional and post-transcriptional steps.

Thyroidal enhancement of rat myocardial Na,K-ATPase: preferential expression of alpha 2 activity and mRNA abundance.

In hypothyroid rat myocardium, the low-ouabain-sensitivity Na,K-ATPase activity had a KI = 10(-4) M and accounted for approximately 95% of the enzyme activity, while the high-ouabain-sensitivity activity contributed approximately 5% to the total activity, with a KI = 3 x 10(-7) M. mRNA alpha 1 was 7.2- and 5.5-fold more abundant than mRNA alpha 2 and mRNA beta, respectively, in hypothyroid ventricles while mRNA alpha 3 was undetectable. Administration of T3 increased total Na,K-ATPase activity 1.6-fold; the low-ouabain-sensitivity activity increased 1.5-fold while high-ouabain-sensitivity activity was stimulated 3.2-fold. T3 increased the number of high-affinity ouabain-binding sites 2.9-fold with no change in Kd (approximately 2 x 10(-7) M). The abundances of mRNA alpha 1, mRNA alpha 2, and mRNA beta (per unit RNA) following T3 treatment increased 3.6-, 10.6-, and 12.7-fold, respectively. The larger increments in subunit mRNA abundances than in Na,K-ATPase activity suggests the involvement of translational and/or post-translational regulatory steps in Na,K-ATPase biogenesis in response to T3. It is concluded that T3 enhances myocardial Na,K-ATPase subunit mRNA abundances and Na,K-ATPase activity, and that the expression of the high- and low-ouabain-sensitivity activities are probably a reflection of the abundances of the alpha 2 and alpha 1 isoforms, respectively. The physiological role played by the beta subunit remains uncertain.

Na,K-ATPase in several tissues of the rat: tissue-specific expression of subunit mRNAs and enzyme activity.

The relative contents of Na,K-ATPase subunit mRNAs in rat renal cortex, ventricular myocardium, skeletal muscle (hind limb), liver and brain (cerebrum) were measured. Expressed per unit DNA, mRNA alpha 1 content was approximately 2-fold greater in the kidney and brain as compared to either heart, skeletal muscle or liver. The hierarchy of mRNA alpha 2 expression was brain > skeletal muscle > heart, whereas mRNA alpha 3 was restricted to brain. Beta 1 subunit mRNA content in both kidney and brain exceeded the abundance of liver mRNA beta 1 by approximately 7-fold. In all tissues examined, the combined abundances of the alpha subunit mRNAs exceeded the content of mRNA beta 1. The hierarchy of Na,K-ATPase activity expressed per unit DNA was brain > kidney > skeletal muscle = heart > liver. The sum of mRNA alpha as well as mRNA beta 1 content, expressed per g of tissue, was highest in brain and kidney. A statistically significant correlation between mRNA beta 1 content and Na,K-ATPase activity was evident.

Increased abundance of Na+-K+-ATPase mRNAs in response to low external K+.

Exposure of ARL 15 cells, an established line from adult rat liver, to external K+ concentrations less than 1 mM for 24 h increases Na+-K+ pump abundance (Na+-K+-ATPase) (J. Gen. Physiol. 87:591-606, 1986). We found that treatment of confluent monolayers of ARL 15 cells with low-K+ medium (0.65 mM) caused a 100% increase in total RNA content per plate after 24 h, as well as a 25% increase in DNA and protein content per plate. Concomitant with this growth effect, low-K+ exposure for 6 h elicited 60% increases in mRNA alpha and mRNA beta, the mRNAs that encode the constituent subunits of the Na+-K+-ATPase, in a polyadenylated RNA fraction. At 24 h, however, the abundance of mRNA alpha increased by 290%, whereas mRNA beta increased by only 70%. Moreover, in both control and low-K+-treated cells, mRNA alpha was 30-fold or more greater in abundance than mRNA beta. This discrepancy in abundance was also present in rat liver, but not in cultured MDCK cells. The differences in abundance of mRNA alpha and mRNA beta suggest that the liver may have an unusual subunit composition or biosynthetic mechanism. Nevertheless, the increases in the abundance of mRNA alpha and mRNA beta are sufficient to account for the observed 70-100% increase in Na+-K+-ATPase activity in response to low external K+.

Kinetic analysis of Na,K-activated adenosine triphosphatase induced by low external K+ in a rat liver cell line.

Exposure of ARL 15 cells to medium containing reduced concentrations of K+ (0.65 mM) elicited a 50-100% increase in Na,K-ATPase activity. The inhibition by ouabain of both the basal and the induced enzyme conformed to a single-site model (KI = 1 x 10(-4) M). The low K+-induced increment in Na,K-ATPase activity was accompanied by an equivalent increase in the abundance of Na,K-pump sites estimated by ouabain-stabilized ("back-door") phosphorylation, such that the calculated catalytic turnover number of approximately 8000/min was minimally changed. Comparison of the dependence of ouabain-inhibitable K+ uptake on intracellular Na+ and on extracellular K+ concentrations in control and low K+-treated cells revealed no change in the respective half-maximal stimulatory concentrations for these cations, whereas the maximal rate of active K+ uptake in cells exposed to low external K+ increased by nearly 100%. The derived Hill coefficients for active K+ transport rate were also unchanged by the low K+ treatment (i.e. approximately 1.4 for extracellular K+ and 2.6 for intracellular Na+). Na,K-ATPase activity of basal and low K+-induced cells calculated from the measured maximal Na,K transport rate closely approximated the Na,K-ATPase activity measured enzymatically in unfractionated cell lysates under Vmax conditions, suggesting that all or most of the Na,K-ATPase enzymatic units present in both basal and stimulated states are functionally active. Northern blot analysis of RNA isolated from control cells indicated the presence of the Na,K-ATPase alpha-I isoform of the enzyme which increased by nearly 200% following incubation of the cells in low-K+ medium. By contrast, the alpha-II and alpha-III mRNAs were undetectable in either the basal or low K+-stimulated state. These results indicate that the Na,K-ATPase induced by incubation of ARL 15 cells in low-K+ medium is kinetically and functionally indistinguishable from the basal enzyme, and that only the alpha-I isoform is expressed under control and low-K+ conditions.

Growth hormone-releasing factor regulates growth hormone mRNA in primary cultures of rat pituitary cells.

A peptide with high intrinsic activity for specifically stimulating the secretion of immunoreactive growth hormone (GH; somatotropin) has been characterized and reproduced by total synthesis. This peptide, human pancreatic growth hormone-releasing factor, 44-amino-acid form (hpGRF1-44-NH2), was isolated from a tumor localized in the pancreas of a patient with acromegaly. We report here the effect of this growth hormone-releasing factor (GRF) on GH release and the GH mRNA levels in monolayer cultures of rat pituitary. The cytoplasmic dot hybridization technique was used to examine the effect of GRF on GH mRNA levels. Incubation of rat pituitary cultures with GRF for 72 hr resulted in a 2- to 2.5-fold increase in GH mRNA levels, and the maximal levels of stimulation were achieved at GRF concentrations as low as 1 fM. GRF did not stimulate prolactin release, nor did it affect specific prolactin mRNA levels in the pituitary cultures. We conclude that GRF is a potent and specific GH secretagogue that also affects specifically GH mRNA levels in normal pituitary cells.